Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK talks about new and emerging drug targets in acute myeloid leukemia (AML). Prof Russell discusses the FLT3 mutation, which is one of the most established targets and has been a focus of research for several years, acute promyelocytic leukemia (APL), as well as the IDH1, IDH2 and NPM1 mutations. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
Author: admin
Gilles Salles, MD, PhD, from South Lyon Hospital Complex, Lyon, France provides an overview of his presentation on ‘chemo-free’ in follicular lymphoma held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland. Prof Salles outlines the limitations of chemotherapy and the reasons why he supports a ‘chemo-free’ approach. He argues that chemotherapy is not curative and that agents that can modify the microenvironment, may be successful at managing the disease. For example, monoclonal antibodies such as anti-CD20, either alone or when combined with chemotherapy, can improve the survival…
Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the tolerability of monoclonal antibodies. According to Prof Martin, monoclonal antibodies are well tolerated, however, at the first infusion there can be infusion-related reactions. Recorded at the Myeloma 2016 meeting held in Boston, MA.
Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of monoclonal antibody therapy in multiple myeloma (MM). Daratumumab and elotuzumab are already approved and according to Prof Martin, the next monoclonal antibody to be approved will be isatuximab. Isatuximab like daratumumab, targets CD38 and responses to the drug in pre-clinical work and clinical trials have been good. In the initial Phase I trial in relapsed/refractory myeloma (NCT01749969), the response rate to isatuximab was over 30% and in combination with lenalidomide and dexamethasone, the response rate was in the 60% range. Prof…
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the use and side effects of venetoclax for multiple myeloma (MM) in clinical practice. Venetoclax is very potent in chronic lymphocytic leukemia (CLL) and Prof Boise describes how patients treated with the drug had to stay in hospital due the associated toxicity. Multiple myeloma patients are also initially treated in hospital during the first cycle but are then able to go home. According to Prof Boise, venetoclax is fairly well tolerated and has also been tested in combination with bortezomib and dexamethasone. Recorded at the Myeloma 2016 meeting held…
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA discusses the possibility of exploiting the biology of the plasma cell for drug therapy in multiple myeloma (MM). Prof Boise mentions the targeting of the cell surface proteins CD28 and CD86 and translating findings into clinical practice. Recorded at the Myeloma 2016 meeting held in Boston, MA.
Faith Davies, MBBCh, MRCP, MD, FRCPath from UAMS Myeloma Institute, Arkansas, AZ discusses the importance of the microenvironemt in multiple myeloma at the Myeloma 2016 meeting held in Boston, MA. In light of findings that have established the importance of the microenvironment, Prof Davies further talks about the possibility of new drug combinations, such as combining HDAC inhibitors with immune check-point inhibitors.
Antonio Palumbo, MD, from the University of Turin, Turin, Italy, provides an overview of his talk on ‘Perspectives on future paths to cure’ held at the Myeloma 2016 meeting in Boston, MA. According to Dr Palumobo, the key message is that the survival of patients with multiple myeloma (MM) has improved over the last 15 years. Dr Palumbo further discusses the prospect of being able to cure a proportion of patients and further highlights that currently, the use of a dose intense treatment at diagnosis is important as with this approach, remission durations of around six or even ten years…
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, discusses multiple immune checkpoint molecules, including PD-L2, gamma interferon, IDO, TIM3 LAG-3 B7H3, that may have clinical relevance for the treatment of patients with lung cancer.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses immunotherapy as a key theme of the conference, including current data and future concepts, efficacy in untreated patients, efficacy in combination approaches, and biomarker-based treatment selection.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the detection of anaplastic lymphoma kinase gene (ALK) rearrangements and fusions in patients with non-small cell lung cancer.
Pages Image Alignment
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, provides an overview of therapeutic approaches based on an increasing molecular level understanding of tumors to overcome acquired resistance in patients with non-small cell lung cancer.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses results from ASCEND-1 and ASCEND-2, two non-randomized phase 1/2 multicenter, open-label, single-arm trials evaluating the efficacy of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, in patients with pretreated, ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, explains that there has been significant progress in the development of immunotherapy for lung cancer and clinical trial design in immunotherapy should be tailored to the patterns of response and outcomes observed for this approach.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses LUX-Lung 7, a phase 2b, global, randomized, open-label trial of afatinib compared with gefitinib as first-line treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial evaluating the combination of chemotherapy and gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Enriqueta Felip, MD, PhD, from Vall dHebron Institute of Oncology, Barcelona, Spain, discusses results from a retrospective study showing the continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses biomarkers, including biomarkers of DNA repair and related pathways, for predicting treatment response to chemotherapy and radiotherapy in patients with non-small cell lung cancer (NSCLC).
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses the characterization of tumor-infiltrating lymphocytes in resectable early stage non-small cell lung cancer (NSCLC) and the application of this understanding for the development of immunotherapy in early stage disease.
Faith Davies, MBBCh, MRCP, MD, FRCPath from UAMS Myeloma Institute, Arkansas, AZ gives an update on the use of trametinib, which is a MEK inhibitor, in multiple myeloma (MM). The response rate was 20% when given as a single agent and around 50% when given in combination with other drugs in patient with a RAS mutation. According to Prof Davies, the question is why the response is not 100% and her group has looked at, for example, clonal heterogeneity and the downstream expression of RAS in attempt to find an answer to this question. There may also be other groups…
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses the various features of multiple myeloma (MM) that make assessing response in myeloma challenging. According to Dr Paiva, myeloma is a heterogeneous disease and the correlation between depth of response and clinical benefit, is not as evident in MM as compared to other malignancies. Further, while minimal residual disease (MRD) levels help assess the prognosis for patients with other malignancies, patients with MRD in MM generally do poorly. In recent years, however, there have been improvements in techniques such as PET-CT, which are helping to improve response assessment. Dr…
Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, gives an overview of matched unrelated donor (MUD) transplantation for acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). MUD transplantation means that the transplant is from an unrelated donor. For AML, a transplant is the only curative treatment to date according to Prof Nagler. The issues with transplantation is graft-versus-host disease (GvHD) and finding an eligible donor. Unrelated donors are volunteers and due to advances in the field of transplantation, outcomes in patients who have received a transplant from an unrelated donor compared to patients who have received a…
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK gives an overview of the field of CAR T-cells. With both allogeneic and autologous CAR T-cells under development questions are being raised about their recommended uses and cost of development.
Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the ‘off the shelf’ use of virus-specific T cell therapy. At the moment, the therapy targets 5 viruses but the aim is to include more viruses over time. Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
Niels van de Donk, MD, PhD, from the University Medical Center, Amsterdam, Netherlands discusses the use and mechanism of action of daratumumab. Daratumumab is an anti-CD38 targeting antibody and has shown high activity in end stage patients with multiple myeloma (MM). Dr van de Donk further explains that it has been shown to eliminate CD38 positive immune suppressor cells. This means that a sub-population of regulatory T-cells, which are CD38 positive, are killed during daratumumab therapy. According to Dr van de Donk, CD38 high regulatory T-cells are very immunosuppressive and the elimination of these kinds of cells by daratumumab, is…
Marta Chesi, PhD, from the Mayo Clinic, Scottsdale, AZ discusses LCL-1 for the treatment of multiple myeloma (MM). LCL-1 has an affinity to the cellular inhibitors of apoptosis, cIAP1 and cIAP2. cIAP1 is frequently deleted in myeloma patients and as Dr Chesi explains, when she first treated transgenic mice with LCL161, she expected that it would promote the growth of myeloma as it activates NF-kappa B. However, she observed the opposite, i.e. the tumor burden was reduced in the mice. She further explains that NF-kappa B was activated in the tumor cells as well as the host, which gave the…
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial of the efficacy and safety of BI 1482694 (HM61713), a third-generation epidermal growth factor receptor (EGFR) mutant-specific tyrosine kinase inhibitor (TKI), for the treatment of patients with T790M-positive non-small cell lung cancer (NSCLC).
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, discusses biomarker-based selection of therapy and the progress in understanding clinically relevant biomarkers in patients with lung cancer.
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, John Murray, a Nurse Clinician at the Christie NHS Foundation Trust, Manchester, UK, talks about a standalone nurses day meeting focused on a bone marrow transplant consent. This session gives a better understanding of how patients decide on agreeing to undergo the procedure, from both psychologist’s and patient’s point of view. With limited time to ask questions during clinic hours this information gives a valuable insight into patient’s motivations.
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Jane Apperley, MD from Imperial College London, London, UK discusses developments leading to gene therapies for the management of graft-versus-host-disease (GvHD) and CAR T-cells designed specifically for Acute Myeloid Leukemia (AML) and Myeloma.
Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses the success of targeted drugs such inotuzumab ozogamicin in adult acute lymphoblastic leukemia (ALL) and suggests that physicians should rapidly adpot these new drugs for clinical use. Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses the history of veno-occlusive disease (VOD) and defibrotide, which was developed to improve survival rates of patients affected by this devastating condition.
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, Jane Apperley, MD from Imperial College London, London, UK gives an overview of EBMT 2016 presentations focused on graft-versus-host-disease (GvHD) and metabolic syndrome.
Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses how inotuzumab ozogamicin is now used as a frontline therapy in adult acute lymphoblastic leukemia (ALL). According to Prof Martinelli, this means that patients can be treated with more intensive chemotherapy later on or receive a bone marrow transplantation to consolidate the therapy. The future will be without chemotherapy according to Prof Martinelli. Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses improvements in supportive care and diagnostics for acute myeloid leukemia (AML). Further work is required to improve outcomes of high-risk patients.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Zoran Gatalica, MD, DSc, from Caris Life Sciences, Phoenix, AZ, discusses a study evaluating the differences in expression of multiple biomarkers of targeted biological therapies, immune checkpoint inhibitors and chemotherapeutic agents between primary and metastatic tumors in patients with non-small cell lung cancer (NSCLC).
The Myeloma 2016 meeting, was held in Boston, MA, between 2224 April. Keith Stewart MB, ChB from the Mayo Clinic, discusses the day 1 highlights with Sagar Lonial, MD of the Winship Cancer Institute, Kenneth Anderson, MD of the Dana-Farber Cancer Institute, and Leif Bergsagel, MD of the Mayo Clinic. Here the experts discuss the possible targets of cellular immunotherapy, using CAR T-cells and BiTE as the vehicles; minimum residual disease (MRD), the new next-generation flow cytometry techniques available and its use in the drug approval process; among other treatment-related topics.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, explains the development of antibodies targeting the programmed death ligand 1 (PD-L1) and its receptor, programmed death 1 (PD-1) for the treatment of patients with non-small cell lung cancer (NSCLC), including clinical trials evaluating the integration of PD-1/PD-L1blocking antibodies with existing standard-of-care approaches.
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the identification of actionable mutations in tumors for the development of personalized medicine for patients with lung cancer, including for the identification of patients with acquired resistance associated with T790M mutation.
Michael P Kosty, MD, FACP, FASCO Medical Director, Scripps Green Cancer Center gives an update on Immunotherapy of Lung Cancer
Dr. Richard Essner, M.D., F.A.C.S. Cedar Sinai Cancer Center Surgical Director, Melanoma Program discusses the New Role of Surgery in the Treatment of Melanoma
Dr.Michael Alvarado, MD and Dr. Rick Baehner, MD present case studies and a presentation on Genomic Update in Hormone Receptor Positive Breast Cancer
Dr. Daniel S. Oh, MD Assistant Professor of Surgery Division of Thoracic Surgery Keck Medical Center of USC discusses how we can improve early stage lung cancer outcomes.
Dr. Jorge J. Nieva, MD Associate Professor of Clinical Medicine University of Southern California discusses a study conducted by Memorial Sloan Cancer Center in where the objectives were Validate the CCP gene signature (CCP score) and a Prognostic Score that identify stage I non-small cell lung cancer patients with a higher risk of cancer-related death after surgical resection
Dr. Samuel J. Klempner, MD Director of Precision Medicine The Angeles Clinic and Research Institute discusses how Diagnostic Dilemmas and Early Barriers Changing the Cancer Classification, Molecular Epidemiology, Response and Resistance Tumor Mutational Load and Immunotherapy, Liquid Biopsies
Dr. Omid Hamid MD of the Chief, Translational Research & Immuno-Oncology Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute discusses how Immuno-Oncology will affect not only melanoma but many other disease states within oncology.
Sybil R. Green, JD, RPh, MHA ACC, LOS, MOS from ASCO discusses how the updated government program called MACRA will affect payments to oncologist in the very near future.
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, discusses the role of personal development and advocacy by healthcare professionals to address inequalities and unmet needs in patients with breast cancer around the world. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Jan-Willem Coebergh, MD, PhD, from Erasmus MC, Rotterdam, the Netherlands, summarises future directions in the epidemiology of breast cancer, including the efforts to systematically assess patient experiences and quality of care. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews